The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue

Physiological Research

Volumn 58, Issue 3, 2009, Pages 319-325

  Bosanska L ^a   Petrak O ^a   Zelinka, T ^a   Mraz M ^a   Widimsky J ^a   Haluzik M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adiponectin; Body weight; Inflammation; Leptin; Pheochromocytoma; Resistin

Indexed keywords

ADIPONECTIN; ADIPONECTIN, HUMAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LEPTIN; RESISTIN; RETN PROTEIN, HUMAN;

ADIPOSE TISSUE; ADRENAL TUMOR; ADRENALECTOMY; ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; DOWN REGULATION; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; TREATMENT OUTCOME; WEIGHT GAIN;

ADIPONECTIN; ADIPOSE TISSUE; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; DOWN-REGULATION; FEMALE; HUMANS; INFLAMMATION; LEPTIN; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; RESISTIN; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 68649094208     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Anderlová K, Doležalová R, Housová J, Bošanská L, Haluzíková D, Křemen J, Škrha J, Haluzík M: influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissuederived hormones in obese women with type 2 diabetes. Physiol Res 56: 579-586, 2007.
2. Anderlová K, Křemen J, Doležalová R, Housová J, Haluzíková D, Kunešová M, Haluzík M: The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. Physiol Res 55: 277-283, 2006.
3. Bottner A, Eisenhofer G, Torpy DJ, Ehrhart-Bornstein M, Keiser HR, Chrousos GP, Bornstein SR: Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients. Metabolism 48: 543-545, 1999.
4. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K: Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54: 2277-2286, 2005.
5. Cong L, Chen K, Li J, Gao P, Li Q, Mi S, Wu X, Zhao AZ: Regulation of adiponectin and leptin secretion and expression by insulin through a PI3K-PDE3B dependent mechanism in rat primary adipocytes. Biochem J 403: 519-525, 2007.
6. Daub KF: Pheochromocytoma: challenges in diagnosis and nursing care. Nurs Clin North Am 42: 101-111, 2007.
7. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88: 5452-5455, 2003.
8. Doležalová R., Haluzík MM, Bošanská L., Lacinová Z., Kasalová Z., Stulc T., Haluzík M: Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol Res 56: 741-748, 2007.
9. Doležalová R, Lacinová Z, Dolínková M, Kleiblová P, Haluzíková D, Housa D, Papežová H, Haluzík M: Changes of endocrine function of adipose tissue in anorexia nervosa: comparison of circulating levels versus subcutaneous mRNA expression. Clin Endocrinol (Oxf) 67: 674-678, 2007.
10. Gifford RW, Jr., Kvale WF, Maher FT, Roth GM, Priestley JT: Clinical features, diagnosis and treatment of pheochromocytoma: a review of 76 cases. Mayo Clin Proc 39: 281-302, 1964.
11. Haffner SM: Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92: 18J-26J, 2003a.
12. Haffner SM: Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 61 (Suppl 1): S9-S18, 2003b.
13. Haluzík M, Pařízková J, Haluzík MM: Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 53: 123-129, 2004.
14. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44: 6-11, 2004
15. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314: 415-419, 2004.
16. Khorram-Manesh A, Ahlman H, Nilsson O, Friberg P, Oden A, Stenstrom G, Hansson G, Stenquist O, Wangberg B, Tisell LE, Jansson S: Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med 258: 55-66, 2005.
17. Kosaki A, Yamada K, Kuzuya H: Reduced expression of the leptin gene (ob) by catecholamine through a G(S) protein-coupled pathway in 3T3-L1 adipocytes. Diabetes 45: 1744-1749, 1996.
18. Kvasnička J, Škrha J, Perušičová J, Kvasnička T, Marková M, Umlaufová A, Pecen L: The occurrence of the cardiovascular risk factors - fibrinogen, t-PA, PAI-1, in insulin-dependent diabetes mellitus (IDDM) and in non-insulin-dependent diabetes mellitus (NIDDM) Cor Vasa 39: 146-150, 1997
19. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM: Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161, 1995.
20. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277: 37487-3791, 2002.
21. Neels JG, Olefsky JM: Inflamed fat: what starts the fire? J Clin Invest 116: 33-35, 2006
22. Pacak K, Ilias I, Adams KT, Eisenhofer G: Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 257: 60-68, 2005.
23. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, Windler E: Association of plasma resistin levels with coronary heart disease in women. Obes Res 13: 1764-1771, 2005.
24. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JS, Raitakari OT: Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. J Intern Med 258: 428-434, 2005.
25. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932-939, 2005.
26. Shimada K, Miyazaki T, Daida H: Adiponectin and atherosclerotic disease. Clin Chim Acta 344: 1-12, 2004.
27. Stoll G, Bendszus M: Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 37: 1923-1932, 2006.
28. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, et al.: Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271, 1995.
29. Trayhurn P, Duncan JS, Rayner DV, Hardie LJ: Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the beta 3-adrenoceptor agonists BRL 35135A and ZD2079. Biochem Biophys Res Commun 228: 605-610, 1996.
30. Ukkola O: Resistin - a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 147: 571-574, 2002
31. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
32. Wocial B, Ignatowska-Switalska H, Berent H, Dutkiewicz-Raczkowska M, Kuczynska K, Chodakowska J, Feltynowski T, Januszewicz W, Szostek M, Ciesla W: Do catecholamines influence the level of plasma leptin in patients with phaeochromocytoma? Br J Biomed Sci 59: 141-144, 2002
33. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, CHEN H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
34. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T: Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278: 2461-2468, 2003.
35. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86: 3815-3819, 2001.
36. Zelinka T, Eisenhofer G, Pacák K: Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Stress 10: 195-203, 2007a.
37. Zelinka T, Petrák O, Štrauch B, Holaj R, Kvasnička J, Mazoch J, Pacák K, Widimský J, Jr.: Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension. Neuroimmunomodulation 14: 57-64, 2007b.
38. Zelinka T, Štrauch B, Pecen L, Widimský J, Jr.: Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 18: 107-111, 2004.